BrainParrot

Commerce and Industry Minister Shri Piyush Goyal Chairs Roundtable on Strengthening India’s Biopharma Startup Ecosystem and Accelerating Bioeconomy Growth

GS3Full notePublished:

Source: PIB (Press Information Bureau) · Read the original ↗

Summary

  • Commerce & Industry Minister Piyush Goyal chaired a high-level roundtable on "India's Bioeconomy Opportunity: Role of Startups in Driving Innovation and Growth" at Vanijya Bhawan, New Delhi.
  • DPIIT organised it in collaboration with NITI Aayog and the NITI Frontier Tech Hub. Policymakers, industry leaders and biopharma startups attended.
  • The discussion was on measures to accelerate bioeconomy growth: regulatory ease, finance, shared infrastructure and coordination. Goyal stressed leveraging India's scientific capabilities and entrepreneurial talent to make India a global bioeconomy leader.

UPSC relevance: GS3 — Economy (industrial policy, startups, regulatory reform) / GS3 — S&T (biotechnology)

Key facts for Prelims

  • The roundtable was organised by DPIIT with NITI Aayog and the NITI Frontier Tech Hub. Venue: Vanijya Bhawan, New Delhi.
  • Biopharma SHAKTI was announced in Union Budget 2026–27. It is a Budget initiative for domestic production of biologics and biosimilars. It includes 3 new NIPERs, 7 upgraded NIPERs and 1,000+ accredited clinical trial sites.
  • CDSCO is the national drug regulator. The Budget proposes to strengthen it with a dedicated scientific review cadre.
  • Regulatory measures discussed: a proposed Regulatory Sandbox, Single Window Clearance, global regulatory alignment, simplified patent application processes.
  • Biologics (vaccines, proteins, gene therapies) differ from biosimilars (highly similar copies of a reference biologic).
  • NITI-FTH is an "action tank" under NITI Aayog. BioE3 is a separate Cabinet-approved biotechnology policy (24 Aug 2024).

Data and details

  • The release itself contains no quantitative targets or market figures.
  • From the Union Budget 2026–27 (not from the release), Biopharma SHAKTI has a ₹10,000 crore outlay over 5 years, with 3 new and 7 upgraded NIPERs and 1,000+ trial sites.
  • Roundtable points listed in the release:
  • Faster approvals and improved access to finance (Goyal).
  • Shared infrastructure (laboratories, testing facilities, clinical trial facilities) to reduce costs and enable startups to scale.
  • Stronger industry–academia–Government collaboration.
  • Time-bound action on the recommendations emerging from the roundtable (Goyal).
  • Strengthening indigenous life sciences manufacturing.
  • Expedited customs clearance for laboratory equipment and reagents.
  • Simplified access to Government schemes and regulatory support.
  • Stronger inter-ministerial coordination, for coherent policy interventions and faster resolution of sector-specific challenges.
  • Named speakers: Ms. Debjani Ghosh, Distinguished Fellow, NITI Aayog (collaboration among startups, industry, academia and Government for a globally competitive bioeconomy). Prof. Gobardhan Das, Member, NITI Aayog (strengthening research capabilities, translating discoveries into commercially viable products).
  • Notably absent: the release gives no decisions, timelines or notified measures. The Regulatory Sandbox is described only as "proposed", so these are recommendations.

Static–dynamic linkage

A "bioeconomy" is the part of the economy that produces goods and services from biological resources and biotechnology. Examples are medicines, industrial bio-products, agri-biotech and research services. Startups in this space face long approval cycles, expensive labs and trials, and patent complexity. Governments therefore use regulatory tools (sandboxes, single-window clearance) and public goods (shared labs, testing and trial facilities) to cut early-stage risk. The roundtable is an instance of this "enabling state" approach to deep-tech industrial policy. Its main focus is regulatory and infrastructure bottlenecks.

Syllabus mapping: GS3 – Economy: industrial policy, investment models, startups/ease of doing business; GS3 – S&T: biotechnology and its applications, IPR; GS2 – Governance: regulatory simplification, inter-ministerial coordination.

Background primer

Biopharma SHAKTI (Union Budget 2026–27)

What it is:
"Strategy for Healthcare Advancement through Knowledge, Technology & Innovation". It is a Budget initiative to develop India as a global biopharma manufacturing hub. It builds the ecosystem for domestic production of biologics and biosimilars.
Founded:
announced in the Union Budget 2026–27, with a focus on India's shifting disease burden towards non-communicable diseases such as diabetes, cancer and autoimmune disorders.
Mandate:
build the ecosystem for domestic production of biologics and biosimilars. This includes strengthening CDSCO to meet global standards and approval timeframes through a dedicated scientific review cadre and specialists.
Why it matters:
to move India up the pharmaceutical value chain, from a cost-efficient generics producer to a hub for innovation-driven biopharma products. It also aims to reduce import dependence.

Biologics vs Biosimilars

NITI Frontier Tech Hub (NITI-FTH)

What it is:
a NITI Aayog body set up to anticipate mega technology shifts and chart India's readiness for inclusive growth, supply-chain resilience and national security. It is described as an "action tank" for Viksit Bharat.
Founded:
announced by NITI Aayog in March 2025 as a Frontier Tech Action Tank.
Mandate:
produce strategies and policy recommendations on frontier-tech readiness. Its outputs include the roadmap "Building India as a Leading BioEconomy Powerhouse by 2035" (July 2026).

DPIIT (Department for Promotion of Industry and Internal Trade)

Additional context

  • BioE3 Policy: The Union Cabinet approved the BioE3 (Biotechnology for Economy, Environment and Employment) Policy on 24 August 2024. It was proposed by the Department of Biotechnology. It aims to establish Biomanufacturing and Bio-AI hubs and Biofoundries.
  • National Biopharma Mission: It is led by the Department of Biotechnology and implemented by BIRAC. It has a budget of $250 million, co-funded 50% by the World Bank.
  • Manufacturing schemes already in place (Department of Pharmaceuticals):
    • PLI for Pharmaceuticals (₹15,000 crore).
    • Promotion of Bulk Drug Parks (₹3,000 crore).
    • Strengthening of Pharmaceutical Industry (SPI), which supports MSME technology upgradation and common facilities.
  • Bioeconomy size:
    • IBER 2025 put India's bioeconomy at USD 165.7 billion in 2024 (4.25% of GDP), against a 2030 target of USD 300 billion.
    • Sub-sector split: BioIndustrial 47%, BioPharma 35%, BioAgri 8%, BioResearch 9%.
  • NITI Frontier Tech Hub roadmap (July 2026):
    • It was prepared by NITI-FTH in consultation with the Department of Biotechnology, ABLE and other stakeholders.
    • It puts the bioeconomy at USD 195.3 billion in 2025 and sets targets of USD 691 billion by 2035 and USD 2.6 trillion by 2047.
    • It proposes a ₹50,000-crore BioEconomy Growth Fund (2026–2035) to bridge the "valley of death" between proof-of-concept and scale-up manufacturing.
    • It recommends regulatory sandboxes for frontier modalities, CDSCO modernisation and biotech-specific patent protection measures.

Mains dimensions

  • Regulatory bottleneck: Slow approvals, fragmented clearances and patent complexity raise startup costs. The roundtable's answer is a proposed Regulatory Sandbox (a controlled live-testing space), Single Window Clearance, global regulatory alignment and simpler patent applications. The NITI-FTH roadmap likewise recommends sandboxes and CDSCO modernisation.
  • Infrastructure as a public good: Shared labs, testing and clinical-trial facilities lower fixed costs for capital-light startups. This links to Biopharma SHAKTI's 1,000+ trial-site network.
  • Import dependence and supply chains:
  • The push for indigenous life sciences manufacturing sits alongside customs-clearance delays for lab equipment and reagents. Startups depend on imported inputs, so trade facilitation and self-reliance pull in different directions.
  • Biopharma SHAKTI itself aims to reduce import dependence.
  • Translational gap: Prof. Das's point is that research strength has to become commercially viable products. This points to industry–academia linkages and funding for the "valley of death" stage. The NITI roadmap's proposed ₹50,000-crore BioEconomy Growth Fund targets exactly this gap.
  • Coordination failure: Participants stressed inter-ministerial coordination. Biotech regulation spans Commerce, Health (CDSCO), Biotechnology, Science and Finance (customs). Cooperative federalism and "whole-of-government" delivery are therefore relevant.
  • Challenges and way forward: Finance access for long-gestation biotech, time-bound implementation of recommendations (the Minister's own call), a trained workforce (new and upgraded NIPERs), and clinical-trial credibility.

Possible Mains question

**GS3, 15 marks:** "India's bioeconomy has potential to become a major driver of growth, but startups in the sector face regulatory and infrastructure hurdles. Discuss the policy measures needed to build a globally competitive biopharma startup ecosystem."

Related topics

  • BioE3 Policy; Biotechnology policy and the Department of Biotechnology/BIRAC
  • CDSCO, the Drugs and Cosmetics Act and clinical trial regulation
  • Startup India; regulatory sandboxes (as used in fintech)
  • PLI scheme for pharmaceuticals; Bulk Drug Parks
  • Patents Act and IPR in biotechnology
  • NITI Aayog's role and its other "Hubs"

Topics: GS3

How we write and check these notes →

All current affairs of 3 November 2026 → · UPSC Current Affairs